<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Targeted therapies for CLL &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/targeted-therapies-for-cll/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Thu, 25 Sep 2025 08:59:55 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Targeted therapies for CLL &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Choosing First-Line Therapy for Chronic Lymphocytic Leukemia</title>
		<link>https://bioengineer.org/choosing-first-line-therapy-for-chronic-lymphocytic-leukemia/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 25 Sep 2025 08:59:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Biomarker-driven therapy]]></category>
		<category><![CDATA[Chronic lymphocytic leukemia treatment]]></category>
		<category><![CDATA[First-line therapy selection]]></category>
		<category><![CDATA[Precision oncology in CLL]]></category>
		<category><![CDATA[Targeted therapies for CLL]]></category>
		<guid isPermaLink="false">https://bioengineer.org/choosing-first-line-therapy-for-chronic-lymphocytic-leukemia/</guid>

					<description><![CDATA[In the rapidly evolving landscape of hematologic malignancies, chronic lymphocytic leukemia (CLL) continues to pose intricate challenges regarding the optimal selection of first-line therapies. A recent opinion paper by Carda et al., published in Medical Oncology, sheds critical light on the nuanced criteria that should guide frontline therapeutic strategies in CLL, reflecting a paradigm shift [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">272097</post-id>	</item>
	</channel>
</rss>
